Literature DB >> 27915082

The heart failure pandemic: The clinical and economic burden in Greece.

P Stafylas1, D Farmakis2, G Kourlaba3, G Giamouzis4, K Tsarouhas4, N Maniadakis5, J Parissis2.   

Abstract

BACKGROUND: The objective of this study was to identify the epidemiological and clinical characteristics of heart failure (HF) patients in Greece as well as the economic burden and the distribution of costs for the management of the disease.
METHODS: Eight Greek secondary and tertiary cardiology centres from different cities have participated in a prospective, observational survey, the ESC HF Pilot Survey. 307 patients with HF, 177 hospitalised and 130 outpatients, have been recruited and monitored for 12months. Clinical and epidemiological data, along with data on mortality, hospitalisations and health care resources used have been collected. The economic evaluation was conducted from the social security system perspective.
RESULTS: The annual mortality rate was 24.3% for the hospitalised patients vs 7.7% for the outpatients (P<0.001) and the annual rehospitalisation rate was 42.9% vs 19.2% respectively (P<0.001). Kaplan-Meier analyses revealed that patients with kidney dysfunction, S3 gallop and higher NYHA class have a significantly worse survival. The mean annual economic burden of the social security system per HF patient was estimated at €4411±4764. About two thirds of this cost is due to in-patient care.
CONCLUSIONS: Despite the progress in the management of the disease, about one in four hospitalised patients dies and four in ten are rehospitalised in less than one year. Moreover, the disease imposes a significant economic burden for the social security system and national economy. Their findings suggest that there is still need of more effective drug treatment and efficient disease management programs focused in the reduction of the hospital admissions.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Cost; Economic burden; Epidemiology; Heart failure; Hospitalisations

Mesh:

Year:  2016        PMID: 27915082     DOI: 10.1016/j.ijcard.2016.10.042

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

1.  A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Authors:  Steve Ryder; Kathleen Fox; Pratik Rane; Nigel Armstrong; Ching-Yun Wei; Sohan Deshpande; Lisa Stirk; Yi Qian; Jos Kleijnen
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries.

Authors:  Hamraz Mokri; Ingelin Kvamme; Linda de Vries; Matthijs Versteegh; Pieter van Baal
Journal:  Eur J Health Econ       Date:  2022-08-04

Review 3.  Hospice Use Among Patients with Heart Failure.

Authors:  Sarah H Cross; Arif H Kamal; Donald H Taylor; Haider J Warraich
Journal:  Card Fail Rev       Date:  2019-05-24

4.  Assessment of quality of life and anxiety in heart failure outpatients.

Authors:  Maria Polikandrioti; Georgios Panoutsopoulos; Athanasia Tsami; Georgia Gerogianni; Sofia Saroglou; Efthalia Thomai; Ioannis Leventzonis
Journal:  Arch Med Sci Atheroscler Dis       Date:  2019-04-12

5.  Facing up to the challenges of acute heart failure.

Authors:  Piero Pollesello
Journal:  Eur Heart J Suppl       Date:  2020-05-15       Impact factor: 1.803

6.  The effect of nurse-led interventions on re-admission and mortality for congestive heart failure: A meta-analysis.

Authors:  Xiaoqin Qiu; Chunhan Lan; Jinhua Li; Xi Xiao; Jinlian Li
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

7.  Acute onset heart failure due to reverse type Takotsubo cardiomyopathy caused by a single dose of 4-Fluoroamphetamine in a healthy young individual.

Authors:  R S D van der Pas; F M J Gresnigt; L Wansink; E J F Franssen; R K Riezebos
Journal:  Toxicol Rep       Date:  2020-12-03

Review 8.  The management of atrial fibrillation in heart failure: an expert panel consensus.

Authors:  Dimitrios Farmakis; Christina Chrysohoou; Gregory Giamouzis; George Giannakoulas; Michalis Hamilos; Katerina Naka; Stylianos Tzeis; Sotirios Xydonas; Apostolos Karavidas; John Parissis
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

Review 9.  Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions.

Authors:  Grigorios Tsigkas; Anastasios Apostolos; Stefanos Despotopoulos; Georgios Vasilagkos; Eleftherios Kallergis; Georgios Leventopoulos; Virginia Mplani; Periklis Davlouros
Journal:  Heart Fail Rev       Date:  2021-07-04       Impact factor: 4.654

10.  Cost-of-illness studies in heart failure: a systematic review 2004-2016.

Authors:  Wladimir Lesyuk; Christine Kriza; Peter Kolominsky-Rabas
Journal:  BMC Cardiovasc Disord       Date:  2018-05-02       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.